{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:32:32Z","timestamp":1788942752805,"version":"build-2803163510"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Intramural Research Program of the National Institutes of Health"},{"name":"Cooperative Study of Late Effects for SCD Curative Therapies","award":["COALESCE, 1U01HL156620-01, NHLBI"],"award-info":[{"award-number":["COALESCE, 1U01HL156620-01, NHLBI"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title\/>\n                    <jats:p>The morbidity and mortality of sickle cell disease (SCD) remain high. Novel nonmyeloablative haploidentical hematopoietic cell transplant (HCT) regimens are being proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This report compared the effect of adding an IV pentostatin and oral cyclophosphamide (PC) preconditioning to the nonmyeloablative NIH HCT platform of alemtuzumab and total body irradiation (TBI) in adults with severe SCD. Transplant outcomes were compared to a historical HCT cohort that did not receive the PC preconditioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine adult SCD patients were included. The median age was 33 years, 61% were male, and 92% were HbSS genotype. The median follow-up was 6.5 years. Many patients had severe end-organ damage, including dialysis-dependent end-stage kidney disease (8%) and cirrhosis (10%). One-year overall survival was 95%. The PC regimen was associated with a reduction in acute rejection one-year post-HCT (5% vs. 44%; p\u2009=\u20090.004) and lower graft failure rates throughout the follow-up period. After a median follow-up of 5.2 years, the disease-free survival was 71% for the PC regimen. The PC preconditioning was associated with higher rates of full donor chimerism at 2-years post-HCT (0% vs. 43%; p\u2009=\u20090.02). Grade II-IV acute graft-versus-host disease (GVHD) rates were low; no patients developed moderate to severe chronic GVHD. There remain no cases of myeloid malignancy after PC. With the increased immunosuppression of PC, 23% of patients developed post-transplant lymphoproliferative disorder, 19% developed immune cytopenias, and 62% had viral reactivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec202\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Further study to determine an optimal nonmyeloablative haploidentical regimen for SCD patients with compromised organ function is imperative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Clinical trial registry<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT00977691, NCT03077542).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0332282","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:30:16Z","timestamp":1774287016000},"page":"e0332282","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1591-2451","authenticated-orcid":true,"given":"Emily","family":"Limerick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Queen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lacy","family":"Grecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynona","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7167","authenticated-orcid":true,"given":"Courtney D.","family":"Fitzhugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"2","key":"pone.0332282.ref001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.24598","article-title":"Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease","volume":"92","author":"S Chaturvedi","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"pone.0332282.ref002","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"DS Darbari","year":"2006","journal-title":"Am J Hematol"},{"issue":"6","key":"pone.0332282.ref003","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"MR DeBaun","year":"2019","journal-title":"Blood"},{"issue":"11","key":"pone.0332282.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141706","article-title":"Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia","volume":"10","author":"CD Fitzhugh","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0332282.ref005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ajh.21569","article-title":"Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease","volume":"85","author":"CD Fitzhugh","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"pone.0332282.ref006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"S Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"4","key":"pone.0332282.ref007","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe","volume":"102","author":"P Maitra","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"pone.0332282.ref008","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"OS Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0332282.ref009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"DR Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"pone.0332282.ref010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"DR Powars","year":"1991","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0332282.ref011","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study","volume":"93","author":"S Chaturvedi","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"pone.0332282.ref012","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.14015","article-title":"Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines","volume":"173","author":"N Couque","year":"2016","journal-title":"Br J Haematol"},{"issue":"17","key":"pone.0332282.ref013","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"CT Quinn","year":"2010","journal-title":"Blood"},{"issue":"7","key":"pone.0332282.ref014","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"P Telfer","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"pone.0332282.ref015","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"E Gluckman","year":"2017","journal-title":"Blood"},{"issue":"6","key":"pone.0332282.ref016","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.hoc.2022.06.007","article-title":"Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure","volume":"36","author":"RA Lawal","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"pone.0332282.ref017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"M Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0332282.ref018","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.27295","article-title":"Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients","volume":"99","author":"M Damlaj","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"pone.0332282.ref019","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia","volume":"2","author":"MC Walters","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"pone.0332282.ref020","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"H Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0332282.ref021","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"J Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0332282.ref022","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"J Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"11","key":"pone.0332282.ref023","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"CD Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"pone.0332282.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"pone.0332282.ref025","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative","volume":"25","author":"J de la Fuente","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"pone.0332282.ref026","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-017-0077-1","article-title":"Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide","volume":"53","author":"H Frangoul","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"pone.0332282.ref027","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"AA Kassim","year":"2024","journal-title":"Blood"},{"issue":"1","key":"pone.0332282.ref028","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbmt.2017.08.039","article-title":"HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease","volume":"24","author":"AB Pawlowska","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"pone.0332282.ref029","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease","volume":"24","author":"SL Saraf","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"pone.0332282.ref030","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical bone marrow transplantation for sickle cell disease","volume":"4","author":"AA Kassim","year":"2025","journal-title":"NEJM Evid"},{"issue":"17","key":"pone.0332282.ref031","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"CD Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"12","key":"pone.0332282.ref032","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"A Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"pone.0332282.ref033","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bbmt.2010.11.029","article-title":"The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection","volume":"17","author":"J Mariotti","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"pone.0332282.ref034","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-15-0340","article-title":"High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses","volume":"21","author":"ME Mossoba","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0332282.ref035","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/apt.13347","article-title":"Liver injury is associated with mortality in sickle cell disease","volume":"42","author":"JJ Feld","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"pone.0332282.ref036","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"SO Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"pone.0332282.ref037","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/v16081294","article-title":"EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients and its impact on HSCT outcomes","volume":"16","author":"N Law","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"pone.0332282.ref038","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood.V99.3.850","article-title":"Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait","volume":"99","author":"EM Kang","year":"2002","journal-title":"Blood"},{"issue":"24","key":"pone.0332282.ref039","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"MM Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0332282.ref040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1703162","article-title":"Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing","volume":"28","author":"F Nollet","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"pone.0332282.ref041","article-title":"A Class of $K$-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"RJ Gray","year":"1988","journal-title":"Ann Statist"},{"key":"pone.0332282.ref042","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2023-189914","article-title":"Excellent Outcomes of HLA matched related donor transplant for adults with severe sickle cell disease using a non-myeloablative conditioning with thiotepa and post-transplant cyclophosphamide: multi-center international experience","volume":"142","author":"R Alasbali","year":"2023","journal-title":"Blood"},{"key":"pone.0332282.ref043","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-192022","article-title":"Reduced intensity haploidentical bone marrow transplantation in adults with severe sickle cell disease: BMT CTN 1507","volume":"142","author":"AA Kassim","year":"2023","journal-title":"Blood"},{"issue":"4","key":"pone.0332282.ref044","article-title":"Characterizing immune-mediated cytopenias after allogeneic hematopoietic cell transplantation for pediatric nonmalignant disorders","volume":"27","author":"RT Galvin","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"pone.0332282.ref045","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood-2022-165229","article-title":"Outcomes of Non-Myeloablative HLA-haploidentical bone marrow transplant with thiotepa and post-transplant cyclophosphamide in children and adults with sickle cell disease, a phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)","volume":"140","author":"AA Kassim","year":"2022","journal-title":"Blood"},{"issue":"4","key":"pone.0332282.ref046","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bmt.2016.335","article-title":"Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation","volume":"52","author":"C Pittman","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"pone.0332282.ref047","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2025.02.021","article-title":"Two Nonmyeloablative HLA-matched related donor allogeneic hematopoietic cell transplantation regimens in patients with severe sickle cell disease","volume":"31","author":"Z Inam","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"pone.0332282.ref048","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41409-023-02129-7","article-title":"Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT","volume":"59","author":"J Styczynski","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"pone.0332282.ref049","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14712598.2023.2196366","article-title":"Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation","volume":"23","author":"A Marjanska","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"pone.0332282.ref050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbmt.2009.10.008","article-title":"Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation","volume":"16","author":"AH Blaes","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"pone.0332282.ref051","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"K Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pone.0332282.ref052","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.17648","article-title":"Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting","volume":"196","author":"M Gabelli","year":"2022","journal-title":"Br J Haematol"},{"key":"pone.0332282.ref053","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fped.2019.00171","article-title":"Autoimmune cytopenias in pediatric hematopoietic cell transplant patients","volume":"7","author":"JA Neely","year":"2019","journal-title":"Front Pediatr"},{"issue":"1","key":"pone.0332282.ref054","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2019.08.018","article-title":"Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases","volume":"26","author":"D Dimitrova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"pone.0332282.ref055","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bmt.1704454","article-title":"A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease","volume":"33","author":"KB Miller","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"pone.0332282.ref056","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/01.TP.0000084869.08639.A0","article-title":"Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation","volume":"76","author":"SZ Pavletic","year":"2003","journal-title":"Transplantation"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:30:24Z","timestamp":1774287024000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332282"}},"subtitle":[],"editor":[{"given":"Le","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332282","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}